Clinical Trial Update: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) [Phase 3]

View source ↗

Summary

Phase 3 randomized trial (X-TOLE3) comparing XEN1101 to placebo in focal onset seizures; enrollment is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Onset Seizures

Drugs mentioned

• XEN1101

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Focal Onset Seizures | Phase 3 | Status: RECRUITING